세계의 SGLT2 억제제 시장 : 산업규모, 점유율, 동향, 기회, 예측, 약제별, 적응증별, 지역별, 경쟁별(2020-2030년)

SGLT2 Inhibitors Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others), By Indication (Type 2 Diabetes, Cardiovascular, Others), By Region and Competition, 2020-2030F

US $ 4,500 ￦ 6,295,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 5,500 ￦ 7,693,000

PDF and Excel (Multi-User License)

PDF 및 Excel 보고서를 기업의 팀이나 기관에서 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다.

US $ 8,000 ￦ 11,191,000

PDF and Excel (Custom Research License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 및 Excel 이용 범위와 동일합니다. 80시간의 애널리스트 타임이 포함되어 있고 Copy & Paste 가능한 PPT 버전도 제공됩니다. 짧은 Bespoke 리서치 프로젝트 수행에 맞는 라이선스입니다.

한글목차

세계의 SGLT2 억제제 시장은 2024년에 153억 7,000만 달러로 평가되었고, CAGR 5.90%로 성장할 전망이며, 2030년에는 214억 4,000만 달러에 이를 것으로 예측됩니다.

이러한 경구용 항당뇨병제는 신장을 통한 포도당 배설을 촉진하여 혈당 수치를 낮추는 능력과 함께 체중 감소 및 심혈관 위험 감소와 같은 추가적인 이점을 제공하기 때문에 선호되는 치료 옵션으로 부상했습니다.

시장 개요
예측 기간	2026-2030년
시장 규모 : 2024년	153억 7,000만 달러
시장 규모 : 2030년	214억 4,000만 달러
CAGR : 2025-2030년	5.90%
급성장 부문	자디언스
최대 시장	북미

당뇨병 발병률 증가와 함께 혈당 조절 불량과 관련된 합병증에 대한 인식이 높아지면서 효과적이고 내약성이 우수한 치료 옵션을 요구하는 환자군이 확대되고 있습니다. 강력한 성장 전망에도 불구하고 높은 치료 비용, 엄격한 규제 요건, 요로 감염 및 케톤산증과 같은 부작용에 대한 우려와 같은 도전 과제들이 시장 확장을 어느 정도 제한할 수 있습니다.

주요 시장 성장 촉진요인

의료 산업 성장

주요 시장 과제

치료비 급등

주요 시장 동향

당뇨병 유병률 상승

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 SGLT2 억제제 시장에 미치는 영향

제5장 세계의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율 및 예측
  • 약제별(자디언스, 파미가, 임페파, 인보카나, 기타)
  • 적응증별(2형 당뇨병, 심혈관 질환, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 SGLT2 억제제 시장 전망

• 시장 규모와 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 합병과 인수
• 제품 출시
• 최근 동향

제13장 혼란: 분쟁, 유행, 무역 장벽

제14장 세계의 SGLT2 억제제 시장 : SWOT 분석

제15장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제16장 경쟁 구도

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

제17장 전략적 제안

제18장 기업 소개와 면책사항

HBR

영문 목차

영문목차

Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 15.37 Billion
Market Size 2030	USD 21.44 Billion
CAGR 2025-2030	5.90%
Fastest Growing Segment	Jardiance
Largest Market	North America

Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.

Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.

Key Market Challenges

High Cost of Therapy

One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.

The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.

Key Market Trends

Rising Prevalence of Diabetes

The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.

Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.

Key Market Players

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

SGLT2 Inhibitors Market, By Drug:

• Jardiance
• Farmiga
• Inpefa
• Invokana
• Others

SGLT2 Inhibitors Market, By Indication:

• Type 2 Diabetes
• Cardiovascular
• Others

SGLT2 Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.

Available Customizations:

Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global SGLT2 Inhibitors Market

5. Global SGLT2 Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others)
  • 5.2.2. By Indication (Type 2 Diabetes, Cardiovascular, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America SGLT2 Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Indication
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States SGLT2 Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Indication
  • 6.3.2. Mexico SGLT2 Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Indication
  • 6.3.3. Canada SGLT2 Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Indication

7. Europe SGLT2 Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Indication
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France SGLT2 Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Indication
  • 7.3.2. Germany SGLT2 Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Indication
  • 7.3.3. United Kingdom SGLT2 Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Indication
  • 7.3.4. Italy SGLT2 Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Indication
  • 7.3.5. Spain SGLT2 Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Indication

8. Asia Pacific SGLT2 Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Indication
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China SGLT2 Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Indication
  • 8.3.2. India SGLT2 Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Indication
  • 8.3.3. South Korea SGLT2 Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Indication
  • 8.3.4. Japan SGLT2 Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Indication
  • 8.3.5. Australia SGLT2 Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Indication

9. South America SGLT2 Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Indication
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil SGLT2 Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Indication
  • 9.3.2. Argentina SGLT2 Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Indication
  • 9.3.3. Colombia SGLT2 Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Indication

10. Middle East and Africa SGLT2 Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Indication
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa SGLT2 Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Indication
  • 10.3.2. Saudi Arabia SGLT2 Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Indication
  • 10.3.3. UAE SGLT2 Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global SGLT2 Inhibitors Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Boehringer Ingelheim International GmbH
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. AstraZeneca
• 16.3. Merck & Co., Inc.
• 16.4. Janssen Pharmaceuticals, Inc.
• 16.5. TheracosBio, LLC
• 16.6. Lexicon Pharmaceuticals, Inc.
• 16.7. Eli Lilly and Company
• 16.8. Bristol-Myers Squibb Company
• 16.9. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer

관련자료